

**SUPPLEMENTAL DIGITAL CONTENT 7. Selection of Eligible Individuals to Assess Completion of MenB Vaccine Series**

	Commercial database, n	Medicaid database, n
Individuals in the <i>MarketScan</i> Commercial database with $\geq 1$ claim for MenB-4C or MenB-FHbp during 1/1/2017–11/30/2018	305,161	–
Individuals in the <i>MarketScan</i> Medicaid database with $\geq 1$ claim for MenB-4C or MenB-FHbp during 1/1/2017–9/30/2018	–	111,765
Aged 16–23 years on the index date (first MenB vaccine claim)	288,990	96,114
$\geq 6$ months of continuous enrollment with medical and pharmacy benefits before the index date	242,403	90,517
$\geq 15$ months of continuous enrollment with medical and pharmacy benefits after the index date	183,607	64,163
Without MenB-4C <u>and</u> MenB-FHbp claims during the follow-up period	181,784	63,551
Without a medically high-risk condition during baseline and follow-up*	181,215	63,016
Without a claim for MenB vaccination between 10/1/2014 and 12/31/2016	156,435	57,082
With relationship to employee on index claim as child	156,080	–
Individuals with $\geq 1$ claim for only MenB-4C or only MenB-FHbp	156,080	57,082
Individuals in MenB-4C population	96,059	44,532
Individuals in MenB-FHbp population	60,021	12,550

\*Includes asplenia, persistent complement component deficiency, sickle cell disease, and eculizumab use.

MenB, meningococcal serogroup B, MenB-4C, meningococcal serogroup B 4-component vaccine; MenB-FHbp, meningococcal serogroup B factor H binding protein vaccine; n, number of patients.